Saturday 17 October 2026
Export CRVO’s income statement to Excel — free account
CervoMed Inc.
CRVO Healthcare Biotechnology
CervoMed Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 million, down 58.9% from fiscal 2024. In the quarter to June 2026, revenue fell 99.6%, EPS grew 8.57% and free cash flow fell 6.20%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
2.24
0.01
−0.44%
Follow CRVO
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
2 | 2 | — | — |
| (71.42%) | (93.92%) | (132.76%) | (107.62%) | ||
| (64.37%) | (81.76%) | (111.89%) | (94.73%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(98.36%) | (147.98%) | (282.94%) | (132.18%) | |
Average Days of Receivables |
80.67 | 38.90 | — | — | |
Free Cash Flow per Share |
(2.69) | (2.59) | (2.98) | (2.73) | |
Free Cash Flow |
(24.93) | (23.45) | (27.57) | (27.98) | |
| Other line items | |||||
Cash ROIC |
(46.76%) | (59.99%) | (117.14%) | (58.41%) | |
Accounts Receivable Turnover |
7.58 | 2.99 | — | — | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
374.58% | 544.54% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
167.06% | 261.68% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
24.15% | 36.16% | 0.00% | 0.00% | |
Operating CF/Net income |
0.97 | 0.87 | 0.92 | 0.92 | |
Revenue per Share |
0.67 | 0.44 | 0.00 | 0.00 | |
Operating CF per Share |
(2.69) | (2.59) | (2.98) | (2.73) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | — | — |
Columns are period end dates